Analyst Ratings For Amarin Corporation plc (NASDAQ:AMRN)
Today, Cantor Fitzgerald raised its price target on Amarin Corporation plc (NASDAQ:AMRN) to $35.00 per share.
There are 3 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.
The current consensus rating on Amarin Corporation plc (NASDAQ:AMRN) is Buy with a consensus target price of $21.75 per share, a potential 10.74% upside.
Some recent analyst ratings include
- 9/25/2018-Amarin Corporation plc (NASDAQ:AMRN) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $20.00 price target
Recent Insider Trading Activity For Amarin Corporation plc (NASDAQ:AMRN)
Amarin Corporation plc (NASDAQ:AMRN) has insider ownership of 4.08% and institutional ownership of 38.27%.
- On 10/1/2018 Joseph T Kennedy, General Counsel, sold 50,249 with an average share price of $16.81 per share and the total transaction amounting to $844,685.69.
- On 10/1/2018 Steven B Ketchum, Insider, sold 316,604 with an average share price of $16.13 per share and the total transaction amounting to $5,106,822.52.
- On 9/25/2018 Steven B Ketchum, Insider, sold 879,241 with an average share price of $11.10 per share and the total transaction amounting to $9,759,575.10.
- On 9/24/2018 Joseph S Zakrzewski, Director, sold 500,000 with an average share price of $10.60 per share and the total transaction amounting to $5,300,000.00.
- On 9/24/2018 Joseph T Kennedy, General Counsel, sold 1,079,706 with an average share price of $10.56 per share and the total transaction amounting to $11,401,695.36.
- On 9/24/2018 Michael Wayne Kalb, CFO, sold 150,000 with an average share price of $10.42 per share and the total transaction amounting to $1,563,000.00.
- On 7/2/2018 Joseph T Kennedy, General Counsel, sold 26,942 with an average share price of $3.00 per share and the total transaction amounting to $80,826.00.
About Amarin Corporation plc (NASDAQ:AMRN)
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.
Recent Trading Activity for Amarin Corporation plc (NASDAQ:AMRN)
Shares of Amarin Corporation plc closed the previous trading session at 19,85 −0,44 2,17 % with 20.1 shares trading hands.